# Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

> **NCT05218499** · PHASE2,PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 400 (actual)

## Conditions studied

- Liposarcoma, Dedifferentiated

## Interventions

- **DRUG:** Brigimadlin
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT05218499
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-31
- **Primary completion:** 2024-04-16
- **Final completion:** 2026-01-26
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05218499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05218499, "Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05218499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*